Pfizer's COVID-19 Vaccine Raises Hopes With Over 90% Effectiveness
Pfizer's COVID-19 Vaccine Raises Hopes With Over 90% Effectiveness
Taking a big jump towards delivering an effective vaccine to fight COVID-19 pandemic, US-based pharmaceutical major Pfizer and German biotech firm BioNTech on Monday said that their vaccine candidate was found to be more than 90 per cent effective in preventing COVID-19 in first interim analysis of data from late stage Phase-3 trial.
Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine.
Pfizer Chairman and CEO Albert Bourla called the development "a great day for science and humanity."
According to preliminary findings, protection in patients was achieved seven days after the second of two doses, and 28 days after the first.
"The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19," Albert Bourla said in a statement.
"We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis," he said. "We are reaching this critical milestone in our vaccine development program at a time when the world needs it most."